Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3052766 | 0.97 | TAAR1 (0.95) | TAAR1MAPK1KCNN4CYP1A2CYP3A4 | |
| SCHEMBL17906516 | 0.86 | TAAR1 (0.75) | TAAR1CYP1A2CYP3A4CYP2D6PRMT1 | |
| SCHEMBL6562809 | 0.86 | TAAR1 (0.75) | TAAR1CYP1A2CYP3A4CYP2D6PRMT1 | |
| Hydrochloric Acid SCHEMBL6563360 | 0.83 | TAAR1 (0.71) | TAAR1CYP1A2CYP3A4CYP2D6PRMT1 | |
| SCHEMBL2593641 | 0.82 | TAAR1 (0.70) | TAAR1CYP1A2CYP3A4CYP2D6PRMT1 | |
| SCHEMBL13886626 | 0.81 | TAAR1 (0.67) | TAAR1MAPK1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5147319 | 0.80 | TAAR1 (0.67) | TAAR1KCNN4CYP3A4CYP2D6KIF11 | |
| SCHEMBL460018 | 0.79 | TAAR1 (0.65) | TAAR1MAPK1KCNN4CYP1A2CYP3A4 | |
| SCHEMBL10505310 | 0.79 | TAAR1 (0.65) | TAAR1MAPK1KCNN4CYP1A2CYP3A4 | |
| SCHEMBL9505717 | 0.79 | TAAR1 (0.65) | TAAR1MAPK1KCNN4CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110585165-B | Abuse resistant capsules | R·P·谢勒技术有限公司 | 2022-08-12 | — | — | CN | claimed |
| CN-112209991-B | Tripeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2022-08-12 | — | — | CN | claimed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | claimed |
| JP-2009517533-A | — | — | 2009-04-30 | — | — | JP | claimed |
| WO-2007075251-A2 | WATER-BLOWN, FLAME RETARDANT RIGID POLYURETHANE FOAM | BAYER MATERIALSCIENCE LLC (US) | 2007-07-05 | — | — | WO | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2024150676-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION | 富士フイルム株式会社 | 2024-07-18 | — | — | WO | disclosed |
| EP-3661918-B1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | RECURIUM IP HOLDINGS LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-0035389-B1 | PROCESS FOR PREPARING INTEGRAL SKIN MICROCELLULAR POLYESTER BASE POLYURETHANE ELASTOMERS, THE ELASTOMERS PER SE ISOCYANATE CURABLE COMPOSITIONS AND TWO COMPONENT COMBINATIONS FOR PRODUCING THE ELASTOMERS AND CAST SHOE SOLES ATTACHED TO SHOE UPPERS | PLASTICS TECHNOLOGY ASSOCIATES, INC. (US) | 1986-06-04 | — | — | EP | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
| US-4129580-A | Resolution of certain asymmetric primary amines using lasalocid | HOFFMANN-LA ROCHE INC. (US) | 1978-12-12 | — | — | US | disclosed |
| US-4127588-A | Sulphur containing derivatives | HOFFMANN-LA ROCHE INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-RE29324-E | N-Substituted aspartyl peptide amides | G. D. SEARLE & CO. (US) | 1977-07-26 | — | — | US | disclosed |
| US-4025551-A | 3-Amino-N-substituted succinamic acids | G. D. SEARLE & CO. (US) | 1977-05-24 | — | — | US | disclosed |
| US-4011260-A | 3-AMINO-N-SUBSTITUTED SUCCINAMIC ACIDS AND INTERMEDIATES THERETO | G. D. SEARLE & CO. (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | TAAR1 3590/4885MAPK1 1937/4885KCNN4 4113/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | TAAR1 2181/4885MAPK1 3157/4885KCNN4 74/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | TAAR1 2181/4885MAPK1 3157/4885KCNN4 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.